Recent advances in HCC treatment rely on physical therapies, such as trans-arterial radioembolization with 90Ytrium, improved molecular targeted therapies such as multi-kinase inhibitors, and immune-modulation by anti-Programed Death Ligand 1 (anti-PD-L1) or anti-Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4). This evidence concerns the gene CD274 and hepatocellular carcinoma.